<DOC>
	<DOCNO>NCT02721784</DOCNO>
	<brief_summary>The evaluation radiological change localise locally advanced prostate cancer androgen deprivation therapy external beam radiotherapy use multi-parametric MRI ( multi parametric magnetic resonance imaging ) VERDICT ( Vascular , Extracellular Restricted Diffusion Cytometry Tumours ) sequence .</brief_summary>
	<brief_title>Serial mpMRI ( Multi Parametric Magnetic Resonance Imaging ) Scanning Prostate Cancer After Androgen Deprivation Therapy RadioTherapy</brief_title>
	<detailed_description>External beam radiotherapy ( EBRT ) fail eradicate prostate cancer 24-33 % case . Response monitor solely test serum prostate specific antigen ( PSA ) , biochemical failure follow radiotherapy define prostate specific antigen ( PSA ) level 2 ng/ml nadir . T2 Dynamic Contrast Enhanced ( DCE ) MRI show able detect recurrence prostate cancer follow radiotherapy . Changes see Apparent Diffusion Coefficient ( ADC ) variables post-treatment potential use monitor disease response radiotherapy natural history change treatment remain uncertain warrant investigation . This study investigate feasibility use multi-parametric MRI ( mpMRI ) novel diffusion-weighted sequence call VERDICT ( Vascular , Extracellular Restricted Diffusion Cytometry Tumours ) various stage treatment prostate cancer radiotherapy . Patients first scan androgen deprivation therapy ( ADT ) start , 3 week start radiotherapy , week 6 radiotherapy 6 month end radiotherapy . In addition , patient enter study already mpMRI scan prior prostate biopsy part standard care . Multi-parametric MRI VERDICT sequence may reveal change tumour normal prostate detectable PSA increase . This could allow use response assessment follow radiotherapy androgen deprivation treatment . If clinical utility proven , referral salvage treatment use High Intensity Focussed Ultrasound ( HIFU ) , cryotherapy salvage radical prostatectomy may expedite .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>1 . Targeted Concordant biopsy confirm prostate cancer 2 . Prebiopsy mpMRI scan prostate undertaken University College London Hospital ( UCLH ) 3 . Agrees ADT EBRT 1 . Treatment within previous 6 month form hormone ( include 5alpha reductase inhibitor ) 2 . Evidence metastatic disease 3 . Prior local intervention prostate 4 . Unable give inform consent 5 . Any prosthesis ( include hip replacement ) could cause artefact degrade quality image 6 . Contraindication gadolinium contrast agent 7 . Unable tolerate MRI</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>MRI</keyword>
	<keyword>Radiotherapy</keyword>
</DOC>